The Operational Challenge Of Concurrent Shelf Life Extensions
By Joseph G. Oberlander, Ph.D., PMP, pharmaceutical development consultant and program manager
In clinical development, few announcements generate as much quiet optimism as a successful shelf life extension for an investigational medicine. Additional stability data can preserve valuable inventory, postpone expensive manufacturing campaigns, reduce waste, and provide greater flexibility for trial execution. For small biopharma companies operating with limited resources, every additional month of approved shelf life can appear to be an important strategic win.
However, what often looks like a straightforward scientific success can quickly become a significant operational challenge. The reality is that shelf life extensions rarely occur in isolation. They frequently emerge while regulatory submissions are under review, while countries are moving through activation processes, and while clinical supply teams are trying to ensure that patients have uninterrupted access to treatment. When multiple shelf life extensions occur during the start-up phase of a global study, the complexity can multiply rapidly.
As someone working in clinical supply, I believe the industry consistently underestimates the impact of concurrent shelf life extensions on global country activation. Too often, organizations treat stability updates as technical regulatory events that can simply be managed through amendments and labeling updates. In reality, shelf life strategy should influence country activation strategy from the earliest stages of trial planning.
Organizations that fail to recognize this relationship can find themselves spending enormous amounts of time and money managing avoidable operational disruptions. The fundamental problem is that clinical development timelines and stability programs evolve at different speeds. A clinical team may be focused on accelerating first-patient-in milestones while regulatory teams are actively pursuing approvals in multiple regions. At the same time, the chemistry and manufacturing organization may continue generating new stability data that supports longer storage periods.
When Shelf Life Extensions Create Multiple Supply Realities
By the time one country approves a trial using an 18-month shelf life, another country may receive a submission package reflecting a 24-month shelf life, while still another market may be reviewing an amendment requesting an extension. The result is that a single global trial can begin operating with multiple versions of regulatory reality.
This situation creates challenges that extend far beyond stability science. Inventory dating may differ across regions. Labels may contain different expiry dates. Depots may receive product under different approval conditions. Importation timelines may consume substantial portions of usable shelf life. Clinical sites may receive instructions that differ from those used in neighboring countries participating in the same study.
From an executive perspective, these challenges represent far more than administrative inconveniences. They affect enrollment timelines, budget forecasts, manufacturing plans, and ultimately the overall probability of successful study execution.
The Operational Work Behind A Shelf Life Extension
Another overlooked aspect of the problem is labeling. Senior leaders often assume that once a shelf life extension has been scientifically justified and regulatorily accepted, implementation is largely complete. Experienced supply professionals know that this assumption is rarely accurate.
The actual implementation phase may involve updating artwork, coordinating translations, obtaining approvals, scheduling packaging vendors, revising depot procedures, reconciling inventory records, retraining sites, and documenting every affected batch. Depending on the geographic footprint of the study, these activities can require months rather than weeks.
This is particularly important in global trials because relabeling capabilities differ significantly between regions. Some countries provide greater operational flexibility than others. Some depots have established relabeling processes, while others rely on centralized packaging facilities. Some regulators may require additional documentation before revised expiry dates can be implemented.
Consequently, a shelf life extension that appears straightforward at headquarters can become highly complex once local execution begins.
Connecting Stability, Regulatory, And Supply Decisions
Perhaps the greatest lesson from concurrent shelf life extensions is that governance matters as much as science. In many organizations, stability data are owned by one team, regulatory filings by another, labeling by a third, and country activation by yet another group. Each function may be operating effectively within its own area of responsibility, yet no single team maintains ownership of the complete picture.
The consequences are predictable. Stability projections are disconnected from enrollment forecasts. Regulatory submissions are disconnected from inventory disposition plans. Country activation decisions are disconnected from future labeling requirements.
What is needed is a more integrated model. Leading organizations increasingly establish cross-functional governance structures that connect stability, quality, regulatory affairs, clinical operations, and supply chain planning. These teams operate from a shared understanding of current shelf life, projected extensions, inventory availability, regulatory status, and country-specific activation risks.
When this level of coordination exists, shelf life extensions become strategic enablers rather than operational disruptions.
The broader biopharma industry is moving toward increasingly complex global studies. Investigational medicines are becoming more specialized, patient populations are becoming more geographically dispersed, and supply chains are becoming more interconnected. Under these conditions, concurrent shelf life extensions will become more common rather than less common.
The companies that manage them most effectively will not necessarily be those with the largest stability programs or the most aggressive activation schedules. They will be the organizations that recognize the relationship between product maturity and market readiness.
From my perspective as a clinical supply professional, this is the central lesson executives should understand. Country activation should never be viewed solely as a regulatory or clinical operations milestone. It is equally a product readiness milestone.
A country is not truly ready simply because approval has been granted. It is ready when compliant, usable inventory can reach patients with sufficient remaining shelf life to support uninterrupted treatment. When viewed through that lens, shelf life extensions cease to be routine regulatory maintenance activities. Instead, they become strategic events that influence where, when, and how clinical trials should expand globally.
For small biopharma companies operating with limited resources and ambitious development timelines, that distinction can make the difference between smooth global execution and years of avoidable operational complexity.
About The Author:
Joseph G. Oberlander, Ph.D., PMP, is an experienced pharmaceutical development consultant and program manager. His consulting experience ranges from preclinical to Phase 3 programs, across multiple therapeutic areas (oncologic, metabolic, CNS) and drug modalities (NCE, biologics, biosimilars, generics, CGT), at clients ranging from virtual startups to large biopharma, and throughout the drug life cycle (from raw materials sourcing to finished goods use) for drug programs with global operations. His consulting focus includes deep expertise in clinical supply chain strategy and distribution logistics and in analytical and stability program management. In addition, he has significant research experience in neurobiology and is a published author contributing to the understanding of inherent biological sex differences in synaptic physiology and how these differences impact drug effects and deepen our understanding of preclinical disease models.